[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fZIAxkfe0drV3fRCrqmwr5nkmPEdTd7yzbcNq9nZy_3E":8,"$fp1PJYeVGYNWP5eN_gEdVXmLjLXh3fQIHKaKXslwZxlU":53,"$fUVC-Fq7j-T3klqZy4a-UrlcnodvgzaK6F7EcAO6ZfTQ":57},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":52},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":17,"coverAcross":23,"content":24,"description":22,"views":25,"likes":26,"isThumbsUp":7,"isCollection":7,"collections":26,"createTime":27,"seoTitle":28,"seoKeywords":29,"seoDescription":30,"shelvesTime":6,"version":26,"menus":31,"menuId":33,"type":13,"quality":51,"commentCount":26,"isComment":13},1397,1,[],"https://cdn.yishi-tong.com/console/store-unknown/7qMmQZ2n7JJM3iC15A8jsrPjck4kZJCX.png","科普号","","全科","医师",476,4,"“减重版”司美格鲁肽在我国上市 谁都可以打吗？","https://cdn.haohuanjiao.com/venue/AI/thirdparty/d12c53c3-e5c9-4be7-bd21-316d6a44826f.jpg","\u003Cp style=\"margin:15px 0\">“减重版”司美格鲁肽在我国已经正式上市，但它并不是人人都可以打的。以下是对其适用人群和禁忌症的详细分析：\u003C/p>\u003Ch3 style=\"margin:20px 0\">\u003Cstrong>适用人群\u003C/strong>\u003C/h3>\u003Cp style=\"margin:15px 0\">“减重版”司美格鲁肽是全球首个且目前唯一用于长期体重管理的胰高糖素样肽-1（GLP-1）受体激动剂周制剂。它主要通过控制下丘脑的食欲中枢，减少食欲，延缓胃的排空，增加饱腹感，从而实现减重效果。适用于符合使用要求的注射者，平均能降低约17%的体重，且效果可持续至少2年。然而，这并不意味着所有人都可以使用该药物进行减重。\u003C/p>\u003Ch3 style=\"margin:20px 0\">\u003Cstrong>禁忌症\u003C/strong>\u003C/h3>\u003Cp style=\"margin:15px 0\">以下人群不适合使用“减重版”司美格鲁肽：\u003C/p>\u003Col style=\"padding: 0 1rem;margin: 1.25rem 1rem 1.25rem 0.4rem\">\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>对药物成分过敏者\u003C/strong>：如果对司美格鲁肽或其任何成分过敏，则不能使用此药物。\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>有甲状腺髓样癌病史或家族史者\u003C/strong>：由于司美格鲁肽可能影响甲状腺的功能，因此有甲状腺髓样癌病史或家族史的人应避免使用。\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>有2型多发性内分泌肿瘤综合征病史者\u003C/strong>：这类疾病与司美格鲁肽的使用有潜在的风险关联。\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>18岁以下儿童\u003C/strong>：由于尚未在18岁以下儿童中进行充分的研究，因此不推荐使用此药物。\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>孕妇和哺乳期妇女\u003C/strong>：为了保障胎儿和婴儿的安全，孕妇和哺乳期妇女应避免使用此药物。\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>有急性胰腺炎病史者\u003C/strong>：司美格鲁肽可能增加急性胰腺炎的风险，因此有急性胰腺炎病史的人应避免使用。\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>胃肠道反应严重者\u003C/strong>：如果之前有严重的胃肠道反应，如恶心、呕吐、腹泻等，使用此药物可能会加重这些症状。\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>肾功能不全者\u003C/strong>：肾功能不全可能影响药物的排泄和代谢，因此不推荐使用此药物。\u003C/p>\u003C/li>\u003C/ol>\u003Ch3 style=\"margin:20px 0\">\u003Cstrong>注意事项\u003C/strong>\u003C/h3>\u003Col style=\"padding: 0 1rem;margin: 1.25rem 1rem 1.25rem 0.4rem\">\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>专业评估\u003C/strong>：在使用“减重版”司美格鲁肽之前，必须经过专业医生的评估，确保符合使用条件。\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>副作用监测\u003C/strong>：在使用过程中，应密切监测可能出现的副作用，如恶心、呕吐、腹胀、腹泻、便秘、低血糖、皮疹、荨麻疹等，并及时就医处理。\u003C/p>\u003C/li>\u003Cli>\u003Cp style=\"margin:15px 0\">\u003Cstrong>科学减重\u003C/strong>：虽然“减重版”司美格鲁肽可以帮助减轻体重，但减重不仅仅是药物治疗的问题。还需要结合科学的饮食和适当的运动，以维持健康的体重。\u003C/p>\u003C/li>\u003C/ol>\u003Cp style=\"margin:15px 0\">综上所述，“减重版”司美格鲁肽在我国已经上市，但并非人人都可以使用。在使用前，请务必咨询专业医生，确保自己符合使用条件，并了解药物的禁忌症和注意事项。\u003C/p>",549,0,"2024-12-12 10:25:47"," “减重版”司美格鲁肽在我国上市，谁都可以打吗？\n"," 减重版司美格鲁肽, 减重药物, 司美格鲁肽，中国上市, 药物适用人群\n"," 减重版司美格鲁肽正式在我国上市，这种新型减重药物是否适用于所有人？本文详细介绍了司美格鲁肽的功能、适用人群及使用注意事项，让你全面了解这一热门减肥药。",[32],{"menuId":33,"menuName":34,"parentId":26,"orderNum":35,"path":36,"component":37,"isFrame":38,"isCache":39,"menuType":40,"visible":13,"status":26,"createDept":6,"remark":17,"createTime":41,"children":42,"columnImage":43,"columnLogo":44,"uncheckedLogo":6,"checkedLogo":6,"isHot":13,"isHome":26,"forceLogin":26,"color":45,"seoTitle":46,"seoKeywords":47,"seoDescription":48,"contentNum":6,"promotionalPoster":49,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":50,"routerPath":36,"componentInfo":37},"1986713082609147906","健康科普",2,"article","/article.html","1","0","T","2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","重大疾病,过敏性疾病",true,{"code":9,"msg":10,"message":6,"data":54,"success":52},{"pageNo":13,"pageSize":55,"result":56,"totalSize":26},10,[],{"code":9,"msg":10,"message":6,"data":58,"success":52},{"authors":59,"appraiseDimensionScoresVos":60},[],[]]